Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin
in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated
with reverse ventricular remodeling, significant improvements in exercise capacity, and
improved health status, as compared with placebo.